Free Float 65,11 %
Shares Float 1,78 B
Shares Outstanding 2,73 B
AMNIOTICS AB (PUBL)
Share · SE0015961016 · A3CSHB (XSTO)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of AMNIOTICS AB (PUBL)
No Price
Share Float & Liquidity
Company Profile for AMNIOTICS AB (PUBL) Share
Amniotics AB (publ) develops, manufactures, and sells stem cell therapies based on mesenchymal stem cells to treat severe life-threatening diseases. The company's lead drug candidate is PulmoStem for the treatment of inflammatory and fibrotic lung disease. It also develops CogniStem for the treatment of CNS indications; NephroStem for the treatment of kidney-specific indications; and CutiStem for the treatment of dermatological indications. The company offers contract development and contract manufacturing services for advanced therapy medicinal products to the pharmaceutical industries, universities, and hospitals. Amniotics AB (publ) was incorporated in 2015 and is based in Lund, Sweden.
Company Data
Name AMNIOTICS AB (PUBL)
Company Amniotics AB (publ)
Website
https://www.amniotics.com
Primary Exchange 
Frankfurt
Frankfurt
WKN A3CSHB
ISIN SE0015961016
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Marcus Larsson
Market Capitalization 15 Mio
Country Sweden
Currency EUR
Employees 0,0 T
Address ScheelevAegen 2, 22381 Lund
IPO Date 2021-07-06
Stock Splits
| Date | Split |
|---|---|
| 06.10.2023 | 681:200 |
| 20.02.2023 | 753:250 |
Ticker Symbols
| Name | Symbol |
|---|---|
| NASDAQ STOCKHOLM AB | AMNI.ST |
| Frankfurt | 66J.F |
More Shares
Investors who hold AMNIOTICS AB (PUBL) also have the following shares in their portfolio:
